Category:

15 March 2024

PHARMANUTRA S.P.A.: THE BOD APPROVES THE DRAFT FINANCIAL STATEMENTS AND THE CONSOLIDATED FINANCIAL STATEMENTS AS AT 31 DECEMBER 2023

26 February 2024

Approval of the merger plan

11 January 2024

EURO 100 MILLION IN REVENUE REACHED IN THE YEAR OF ITS 20TH ANNIVERSARY SINCE ESTABLISHMENT

08 January 2024

LOSS OF SME STATUS

21 December 2023

PUBLICATION OF THE 2024 CORPORATE EVENTS CALENDAR

08 November 2023

MODEL DISCLOSURE FOR TRANSACTIONS IN THE ISSUER’S SECURITIES

06 November 2023

BOD APPROVES INTERIM MANAGEMENT REPORT AS AT 30/09/2023

10 October 2023

PHARMANUTRA S.P.A.: INITIATION OF SHARE BUY-BACK PROGRAM

03 October 2023

PHARMANUTRA S.P.A.: FIRST SALES ON THE US MARKET

19 September 2023

PHARMANUTRA S.P.A.: HALF-YEAR FINANCIAL REPORT AS OF 30 JUNE 2023

12 September 2023

POLICY FOR THE MANAGEMENT OF THE DIALOGUE WITH ALL SHAREHOLDERS OF PHARMANUTRA S.P.A.

11 September 2023

PHARMANUTRA S.P.A.: THE BOD APPROVED THE FIRST HALF FINANCIAL REPORT AS AT 30 JUNE 2023

30 August 2023

PHARMANUTRA S.P.A.: LIPOCET (CETILAR®) GETS THE GREEN LIGHT TO BE CLASSIFIED AS A ‘NOVEL FOOD’ ALSO IN THE UK

03 August 2023

PHARMANUTRA S.P.A.: CETILAR® WITH MARCELL JACOBS HEADING FOR PARIS 2024

17 July 2023

PHARMANUTRA S.P.A.: THE BOARD OF DIRECTORS APPROVES THE 2022 SUSTAINABILITY REPORT AND APPOINTS THE SUSTAINABILITY GOVERNANCE

11 July 2023

PHARMANUTRA S.P.A.: CETILAR® IS RECONFIRMED AS MAIN SPONSOR OF THE PISA SPORTING CLUB FOR 2023-2024

26 May 2023

PHARMANUTRA S.P.A.: CETILAR® SIDE BY SIDE WITH FERNANDO ALONSO

08 May 2023

PHARMANUTRA S.P.A.: BOARD OF DIRECTORS APPROVES INTERIM REPORT TO 31 MARCH 2023

12 April 2023

PHARMANUTRA SIGNS THREE NEW AGREEMENTS FOR THE FOREIGN DISTRIBUTION OF SIDERAL® PRODUCTS

17 March 2023

PHARMANUTRA S.P.A: DEPOSITO DOCUMENTAZIONE PER ASSEMBLEA DEGLI AZIONISTI

16 March 2023

PHARMANUTRA: THE BOD APPROVES THE DRAFT FINANCIAL STATEMENTS AND THE CONSOLIDATED FINANCIAL STATEMENTS AS AT 31 DECEMBER 2022

Sorry, this entry is only available in Italiano.: